<DOC>
	<DOCNO>NCT03087903</DOCNO>
	<brief_summary>Patients take 150 mg GSE product mouth twice daily evaluate every 6 week 3 month , every 3 month thereafter one year .</brief_summary>
	<brief_title>A Study Grape Seed Extract Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising PSA</brief_title>
	<detailed_description>Patients take 150 mg GSE product mouth twice daily form 75 mg capsule Leucoselect Phytosome preparation ; total oral dosage 300 mg GSE per day one year . Patients evaluate every 6 week 3 month , every 3 month thereafter one year . PSA measurement obtain schedule visit patient must double PSA ( compare baseline ) 3 month order continue study . Patients meet criterion continue study treat disease progression one year ( whichever come first ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Grape Seed Extract</mesh_term>
	<criteria>1 . Written inform consent obtain . 2 . Histologically confirm prostate adenocarcinoma . 3 . Evidence rise PSA , 2 separate occasion , least one week apart . Baseline PSA must ≥ 0.2 ng/mL time screen . Radiographic evidence disease allow . 4 . Patients must sufficient PSA time point prior enrollment ( minimum 3 PSA level within six month period ) calculate baseline PSA doubling time . 5 . Patients must active LHRH agonist/antagonist therapy must testosterone level &gt; 50 ng/dL . 6 . Patients must active antiandrogen therapy 5alpha reductase inhibitor . Patients stable dose 5alpha reductase inhibitor benign prostatic hypertrophy least 12 month may continue . They must withdraw study stop study . 7 . Patients candidate local salvage therapy must option pursue discuss ; patient must either decline salvage therapy deem candidate salvage therapy . 8 . Patients PSA recurrence local salvage therapy may participate study . 9 . Patients hormone sensitive disease receive prior androgen deprivation therapy part primary/salvage local treatment patient receive intermittent androgen deprivation therapy allow participate . 10 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 11 . Adequate hematologic function ( absolute neutrophil count [ ANC ] ≥1,500 cells/µL ; hemoglobin ≥9 g/dL , platelet ≥75,000/µL ) . 12 . Adequate renal function ( serum creatinine ≤ 2X upper limit normal ( ULN ) 13 . Adequate hepatic function ( total bilirubin ≤ 2 x upper limit normal [ ULN ] , alanine aminotransferase [ ALT ] ≤ 3xULN , aspartate aminotransferase [ AST ] ≤3 x ULN ) . 14 . Patients continue take take time start study , agree start new ( counter ) herbal supplement regular basis study duration . 15 . Prior chemotherapy prostate cancer ( upfront , adjuvant , etc . ) allow long give hormonerefractory disease . 1 . Patients active surveillance untreated localized disease may participate study . 2 . Inability swallow gelatin capsule , medical condition interferes normal gastrointestinal absorption . 3 . Major surgery , radiation , treatment investigational drug within 2 week study treatment . 4 . Documented hypersensitivity reaction product GSE ( see complete list Appendix 1 ) . 5 . Known chronic infection human immunodeficiency virus ( HIV ) viral hepatitis . 6 . Symptomatic prostate cancer determine cancerrelated pain require narcotic pain medication . 7 . History another cancer exclusionary unless believe likely cure unlikely fatal next 3 year ( e.g . squamous cell carcinoma , superficial bladder cancer , chronic lymphocytic leukemia , etc ) . 8 . Very fast PSA double time le 4 week , absolute PSA &gt; 2 ng/mL .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate Specific Antigen ( PSA )</keyword>
	<keyword>Non-Metastatic Prostate Cancer</keyword>
</DOC>